Last reviewed · How we verify

Rocuronium elective surgery

Diskapi Yildirim Beyazit Education and Research Hospital · Phase 3 active Small molecule

Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the nicotinic acetylcholine receptor on the motor endplate.

Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the nicotinic acetylcholine receptor on the motor endplate. Used for Muscle relaxation during elective surgery under general anesthesia, Facilitation of endotracheal intubation.

At a glance

Generic nameRocuronium elective surgery
Also known asesmeron
SponsorDiskapi Yildirim Beyazit Education and Research Hospital
Drug classNon-depolarizing neuromuscular blocking agent
TargetNicotinic acetylcholine receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhasePhase 3

Mechanism of action

Rocuronium binds to nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from binding and causing muscle depolarization. This results in paralysis of skeletal muscles, which is used during anesthesia to facilitate intubation and maintain muscle relaxation during surgery. The drug's effects are reversible and can be antagonized by acetylcholinesterase inhibitors or newer agents like sugammadex.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: